The Nasdaq Biotech Index is down 23% this year. A whopping 81% of 2015 biotech IPOs trade below issue. Against that backdrop, large biotechs Editas Medicine (NASDAQ:EDIT) and BeiGene (NASDAQ:BGNE) delivered solid first-day returns as the first two IPOs of 2016.